Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + etoposide
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Epirubicin + etoposide is a combination chemotherapy regimen consisting of two cytotoxic agents, epirubicin and etoposide. Epirubicin is an anthracycline antibiotic that intercalates into DNA, inhibiting topoisomerase II and preventing DNA replication and transcription. Etoposide is a topoisomerase II inhibitor that induces DNA strand breaks by stabilizing the enzyme-DNA complex, leading to apoptosis in rapidly dividing cells. This combination has been studied primarily for the treatment of advanced or unresectable hepatocellular carcinoma (HCC), where it has demonstrated activity with manageable toxicity profiles[1][3]. The regimen may also be referred to as "EE" in clinical literature.
- Other names
- epirubicin and etoposideEE regimen
02
Targets
TOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on epirubicin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + etoposide.